Liver Fibrosis in Primary Sjögren’s Syndrome

BACKGROUND: Primary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFL...

Descripción completa

Detalles Bibliográficos
Autores principales: Androutsakos, Theodoros, Voulgaris, Theodoros A., Bakasis, Athanasios-Dimitrios, Koutsompina, Maria-Loukia, Chatzis, Loukas, Argyropoulou, Ourania D., Pezoulas, Vasilis, Fotiadis, Dimitrios I., Papatheodoridis, George, Tzioufas, Athanasios G., Goules, Andreas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240196/
https://www.ncbi.nlm.nih.gov/pubmed/35784296
http://dx.doi.org/10.3389/fimmu.2022.889021
_version_ 1784737477893816320
author Androutsakos, Theodoros
Voulgaris, Theodoros A.
Bakasis, Athanasios-Dimitrios
Koutsompina, Maria-Loukia
Chatzis, Loukas
Argyropoulou, Ourania D.
Pezoulas, Vasilis
Fotiadis, Dimitrios I.
Papatheodoridis, George
Tzioufas, Athanasios G.
Goules, Andreas V.
author_facet Androutsakos, Theodoros
Voulgaris, Theodoros A.
Bakasis, Athanasios-Dimitrios
Koutsompina, Maria-Loukia
Chatzis, Loukas
Argyropoulou, Ourania D.
Pezoulas, Vasilis
Fotiadis, Dimitrios I.
Papatheodoridis, George
Tzioufas, Athanasios G.
Goules, Andreas V.
author_sort Androutsakos, Theodoros
collection PubMed
description BACKGROUND: Primary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD), liver fibrosis (LF) may occur. No studies have explored the occurrence of LF in the context of NAFLD among pSS patients. METHODS: Consecutive pSS patients from the rheumatology outpatient clinic of the Department of Pathophysiology and individuals evaluated in the hepatology outpatient clinic for possible NAFLD serving as comparators underwent transient elastography (TE) to assess LF and liver steatosis (LS). All participants had no overt chronic liver disease. Clinical, demographic, and laboratory data were collected from all participants at the time of TE. RESULTS: Fifty-two pSS patients and 198 comparators were included in the study. The median age (range) of pSS and comparators was 62.5 (30–81) and 55 (19–86) years, respectively. Both groups had similar prevalence regarding type 2 diabetes mellitus, hyperlipidemia, and similar body mass index (BMI). Patients with pSS had less frequently high LS (S2, S3) (27% vs. 62%, p < 0.001) and significant LF (F2–4) [2 (3.8%) vs. 34 (17.2%), p = 0.014] than comparators. Univariable analysis showed that advanced LF was significantly associated with older age, higher LS, greater BMI, and disease status (comparators than pSS); of these, only age was identified as an independent LF risk factor in the multivariable logistic regression analysis. CONCLUSION: Liver fibrosis among pSS patients is most likely not attributed to the disease per se.
format Online
Article
Text
id pubmed-9240196
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92401962022-06-30 Liver Fibrosis in Primary Sjögren’s Syndrome Androutsakos, Theodoros Voulgaris, Theodoros A. Bakasis, Athanasios-Dimitrios Koutsompina, Maria-Loukia Chatzis, Loukas Argyropoulou, Ourania D. Pezoulas, Vasilis Fotiadis, Dimitrios I. Papatheodoridis, George Tzioufas, Athanasios G. Goules, Andreas V. Front Immunol Immunology BACKGROUND: Primary Sjögren syndrome (pSS) is a systemic autoimmune epithelitis, potentially affecting salivary epithelium, biliary epithelium, and hepatocytes. Common immunological mechanisms might cause clinically silent liver inflammation, and combined with non-alcoholic fatty liver disease (NAFLD), liver fibrosis (LF) may occur. No studies have explored the occurrence of LF in the context of NAFLD among pSS patients. METHODS: Consecutive pSS patients from the rheumatology outpatient clinic of the Department of Pathophysiology and individuals evaluated in the hepatology outpatient clinic for possible NAFLD serving as comparators underwent transient elastography (TE) to assess LF and liver steatosis (LS). All participants had no overt chronic liver disease. Clinical, demographic, and laboratory data were collected from all participants at the time of TE. RESULTS: Fifty-two pSS patients and 198 comparators were included in the study. The median age (range) of pSS and comparators was 62.5 (30–81) and 55 (19–86) years, respectively. Both groups had similar prevalence regarding type 2 diabetes mellitus, hyperlipidemia, and similar body mass index (BMI). Patients with pSS had less frequently high LS (S2, S3) (27% vs. 62%, p < 0.001) and significant LF (F2–4) [2 (3.8%) vs. 34 (17.2%), p = 0.014] than comparators. Univariable analysis showed that advanced LF was significantly associated with older age, higher LS, greater BMI, and disease status (comparators than pSS); of these, only age was identified as an independent LF risk factor in the multivariable logistic regression analysis. CONCLUSION: Liver fibrosis among pSS patients is most likely not attributed to the disease per se. Frontiers Media S.A. 2022-06-15 /pmc/articles/PMC9240196/ /pubmed/35784296 http://dx.doi.org/10.3389/fimmu.2022.889021 Text en Copyright © 2022 Androutsakos, Voulgaris, Bakasis, Koutsompina, Chatzis, Argyropoulou, Pezoulas, Fotiadis, Papatheodoridis, Tzioufas and Goules https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Androutsakos, Theodoros
Voulgaris, Theodoros A.
Bakasis, Athanasios-Dimitrios
Koutsompina, Maria-Loukia
Chatzis, Loukas
Argyropoulou, Ourania D.
Pezoulas, Vasilis
Fotiadis, Dimitrios I.
Papatheodoridis, George
Tzioufas, Athanasios G.
Goules, Andreas V.
Liver Fibrosis in Primary Sjögren’s Syndrome
title Liver Fibrosis in Primary Sjögren’s Syndrome
title_full Liver Fibrosis in Primary Sjögren’s Syndrome
title_fullStr Liver Fibrosis in Primary Sjögren’s Syndrome
title_full_unstemmed Liver Fibrosis in Primary Sjögren’s Syndrome
title_short Liver Fibrosis in Primary Sjögren’s Syndrome
title_sort liver fibrosis in primary sjögren’s syndrome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240196/
https://www.ncbi.nlm.nih.gov/pubmed/35784296
http://dx.doi.org/10.3389/fimmu.2022.889021
work_keys_str_mv AT androutsakostheodoros liverfibrosisinprimarysjogrenssyndrome
AT voulgaristheodorosa liverfibrosisinprimarysjogrenssyndrome
AT bakasisathanasiosdimitrios liverfibrosisinprimarysjogrenssyndrome
AT koutsompinamarialoukia liverfibrosisinprimarysjogrenssyndrome
AT chatzisloukas liverfibrosisinprimarysjogrenssyndrome
AT argyropoulououraniad liverfibrosisinprimarysjogrenssyndrome
AT pezoulasvasilis liverfibrosisinprimarysjogrenssyndrome
AT fotiadisdimitriosi liverfibrosisinprimarysjogrenssyndrome
AT papatheodoridisgeorge liverfibrosisinprimarysjogrenssyndrome
AT tzioufasathanasiosg liverfibrosisinprimarysjogrenssyndrome
AT goulesandreasv liverfibrosisinprimarysjogrenssyndrome